DE69330910T2 - Arzneiabgabesystem mit stossweiser freisetzung von partikeln - Google Patents

Arzneiabgabesystem mit stossweiser freisetzung von partikeln

Info

Publication number
DE69330910T2
DE69330910T2 DE69330910T DE69330910T DE69330910T2 DE 69330910 T2 DE69330910 T2 DE 69330910T2 DE 69330910 T DE69330910 T DE 69330910T DE 69330910 T DE69330910 T DE 69330910T DE 69330910 T2 DE69330910 T2 DE 69330910T2
Authority
DE
Germany
Prior art keywords
water
coating
pellets
pct
core
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69330910T
Other languages
English (en)
Other versions
DE69330910D1 (de
Inventor
Chih-Ming Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Andrx Pharmaceuticals LLC
Original Assignee
Andrx Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrx Pharmaceuticals LLC filed Critical Andrx Pharmaceuticals LLC
Application granted granted Critical
Publication of DE69330910D1 publication Critical patent/DE69330910D1/de
Publication of DE69330910T2 publication Critical patent/DE69330910T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69330910T 1992-11-27 1993-11-02 Arzneiabgabesystem mit stossweiser freisetzung von partikeln Expired - Lifetime DE69330910T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/982,761 US5260069A (en) 1992-11-27 1992-11-27 Pulsatile particles drug delivery system
PCT/US1993/010643 WO1994012160A1 (en) 1992-11-27 1993-11-02 Pulsatile particles drug delivery system

Publications (2)

Publication Number Publication Date
DE69330910D1 DE69330910D1 (de) 2001-11-15
DE69330910T2 true DE69330910T2 (de) 2002-04-04

Family

ID=25529482

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69330910T Expired - Lifetime DE69330910T2 (de) 1992-11-27 1993-11-02 Arzneiabgabesystem mit stossweiser freisetzung von partikeln

Country Status (10)

Country Link
US (2) US5260069A (de)
EP (1) EP0670718B1 (de)
JP (1) JPH08506802A (de)
AT (1) ATE206613T1 (de)
AU (1) AU680642B2 (de)
CA (1) CA2149152C (de)
DE (1) DE69330910T2 (de)
ES (1) ES2165869T3 (de)
NZ (1) NZ258012A (de)
WO (1) WO1994012160A1 (de)

Families Citing this family (266)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5549924A (en) 1987-07-17 1996-08-27 Robin Renee Thill Shlenker Method of forming a membrane, especially a latex or polymer membrane, including a deactivating barrier and indicating layer
US5679399A (en) 1987-07-17 1997-10-21 Bio Barrier, Inc. Method of forming a membrane, especially a latex or polymer membrane, including multiple discrete layers
US5314696A (en) * 1991-06-27 1994-05-24 Paulos Manley A Methods for making and administering a blinded oral dosage form and blinded oral dosage form therefor
AU7966694A (en) * 1993-07-21 1996-05-02 University Of Kentucky Research Foundation, The A multicompartment hard capsule with control release properties
US5397574A (en) * 1993-10-04 1995-03-14 Andrx Pharmaceuticals, Inc. Controlled release potassium dosage form
FR2723536A1 (fr) * 1994-08-11 1996-02-16 Seth Pawan Composition permettant une liberation selective d'un principe actif
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US20060067999A1 (en) * 1996-03-25 2006-03-30 Wyeth Extended release formulation
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
JP2001507359A (ja) * 1997-01-03 2001-06-05 エラン コーポレーション ピーエルシー 徐放性シサプリドミニ錠剤製剤
HU224224B1 (hu) * 1997-01-14 2005-06-28 Lts Lohmann Therapie-Systeme Gmbh Expandálható gasztroretentív terápiás rendszer szabályozott hatóanyagfelszabadulással a gyomor-bél traktusban
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
MY125849A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
ATE238774T1 (de) * 1997-10-09 2003-05-15 Dexcel Pharma Technologies Ltd Darreichungsform zur verzögerten, vollständigen wirkstoffabgabe im verdauungstrakt
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
US20040029962A1 (en) * 1997-12-12 2004-02-12 Chih-Ming Chen HMG-COA reductase inhibitor extended release formulation
US6372254B1 (en) * 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
AU772726B2 (en) * 1998-08-12 2004-05-06 Takeda Gmbh Oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
US20010055613A1 (en) * 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
US20090149479A1 (en) * 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
US20090297597A1 (en) * 1998-11-02 2009-12-03 Gary Liversidge Modified Release Ticlopidine Compositions
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
IL142896A0 (en) * 1998-11-02 2002-04-21 Elan Corp Plc Multiparticulate modified release composition
US20080118556A1 (en) * 1998-11-02 2008-05-22 Elan Corporation, Plc Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone
WO2000030446A1 (en) 1998-11-23 2000-06-02 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
US20030170181A1 (en) * 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
JP2002541092A (ja) * 1999-04-06 2002-12-03 ファーマクエスト・リミテッド メチルフェニデートのパルス性送達のための薬学的投薬形態
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
MXPA02004293A (es) 1999-10-29 2002-10-31 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada..
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
GB2370552B (en) * 1999-11-17 2003-08-20 Aquasol Ltd Rigid water soluble containers
AU1556000A (en) * 1999-11-22 2001-06-04 Akzo Nobel N.V. Composition allowing predefined and controlled release of active ingredient, preparation thereof and use
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
AU1724301A (en) 1999-12-23 2001-07-09 Pfizer Products Inc. Hydrogel-driven layered drug dosage form
US6669954B2 (en) 2000-01-25 2003-12-30 John R. Crison Controlled release of drugs
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6632453B2 (en) 2000-02-24 2003-10-14 Advancis Pharmaceutical Corp. Ciprofoxacin-metronidazole antibiotic composition
US6669948B2 (en) 2000-02-24 2003-12-30 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6663891B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Erythromyacin antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
EP1257255A4 (de) * 2000-02-24 2008-07-30 Advancis Pharmaceutical Corp Therapeutisches produkt, dessen gebrauch und herstellung
US6730320B2 (en) 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
US6638532B2 (en) 2000-02-24 2003-10-28 Advancis Pharmaceutical Corp. Tetracycline—doxycycline antibiotic composition
CA2400818C (en) * 2000-02-24 2009-01-06 Advancis Pharmaceutical Corporation Antibiotic and antifungal compositions
US6667042B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Fluroquinilone antibiotic product, use and formulation thereof
US6610328B2 (en) 2000-02-24 2003-08-26 Advancis Pharmaceutical Corp. Amoxicillin-clarithromycin antibiotic composition
US6627222B2 (en) 2000-02-24 2003-09-30 Advancis Pharmaceutical Corp. Amoxicillin-dicloxacillin antibiotic composition
US6667057B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Levofloxacin antibiotic product, use and formulation thereof
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
US6623758B2 (en) * 2000-02-24 2003-09-23 Advancis Pharmaceutical Corp. Cephalosporin-metronidazole antibiotic composition
US7025989B2 (en) * 2000-02-24 2006-04-11 Advancis Pharmaceutical Corp. Multiple-delayed released antibiotic product, use and formulation thereof
JP2003531115A (ja) * 2000-02-24 2003-10-21 アドバンシス ファーマシューティカル コーポレイション インヒビターを有する抗生物質組成物
US6663890B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Metronidazole antibiotic product, use and formulation thereof
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
DE60128215T2 (de) 2000-04-20 2008-01-10 Novartis Ag Beschichtungszusammensetzung zur geschmacksmaskierung
US6551617B1 (en) 2000-04-20 2003-04-22 Bristol-Myers Squibb Company Taste masking coating composition
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US7157095B2 (en) * 2000-10-13 2007-01-02 Advancis Pharmaceutical Corporation Multiple-delayed release antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
US7105174B2 (en) * 2000-10-13 2006-09-12 Advancis Pharmaceutical Corporation Multiple-delayed release anti-neoplastic product, use and formulation thereof
US7108859B2 (en) * 2000-10-13 2006-09-19 Advancis Pharmaceutical Corporation Antineoplastic product, use and formulation thereof
CN100518827C (zh) 2000-10-30 2009-07-29 欧罗赛铁克股份有限公司 控释氢可酮制剂
US7964216B2 (en) 2001-01-12 2011-06-21 Sun Pharma Advanced Research Company Limited Spaced drug delivery system
US20020197314A1 (en) 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
CN1499960A (zh) * 2001-03-13 2004-05-26 ����˹��ҩ�﹫˾ 时间治疗剂型
RU2324475C2 (ru) * 2001-04-10 2008-05-20 Сан Фармасьютикал Индастриз Лимитед Состав, выделяемый в импульсном режиме в заданное время
US6663896B1 (en) 2001-08-01 2003-12-16 Alvin S. Blum Delayed release aspirin for vascular obstruction prophylaxis
US9358214B2 (en) * 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US6500454B1 (en) * 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
US20050025824A1 (en) * 2001-12-14 2005-02-03 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
US6663888B2 (en) * 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
CN1606434A (zh) * 2001-12-19 2005-04-13 株式会社三和化学研究所 控制释放成型品
EP1465591A1 (de) * 2001-12-20 2004-10-13 Advancis Pharmaceutical Corporation Antibiotisches produkt, verwendung und formulierung davon
GB0130518D0 (en) * 2001-12-21 2002-02-06 Univ Gent Pulsed bio-agent delivery systems based on degradable polymer solutions or hydrogels
AU2002236132A1 (en) * 2002-03-05 2003-09-16 Ranbaxy Laboratories Limited Modified release oral pharmaceutical composition
CA2478121A1 (en) * 2002-03-07 2003-09-18 Advancis Pharmaceutical Corporation Antibiotic composition
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US6958161B2 (en) 2002-04-12 2005-10-25 F H Faulding & Co Limited Modified release coated drug preparation
MXPA05000224A (es) * 2002-06-26 2005-06-03 Alza Corp Piston de volumen eficiente, minimamente deformable, para sistemas de suministro osmotico de farmacos.
EP1519717B1 (de) * 2002-07-05 2010-09-29 Temrel Limited Zusammensetzung zur kontrollierten wirkstoffabgabe
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
CA2406592C (en) * 2002-10-04 2003-09-30 Duchesnay Inc. Method of preparing pharmaceutical dosage forms containing multiple active ingredients
AU2003284942A1 (en) * 2002-10-30 2004-06-07 Pharmacia Corporation Oral extended release tablets and methods of making and using the same
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
US6893660B2 (en) * 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
US20040114368A1 (en) * 2002-12-13 2004-06-17 Shyu Shing Jy Light device having rotatable or movable view
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US7153526B2 (en) * 2003-02-26 2006-12-26 Frank Steven R Treatment of gastrointestinal infections
US20060210633A1 (en) * 2003-04-03 2006-09-21 Sun Pharmaceutical Industries Limited Programmed drug delivery system
JP2006522099A (ja) * 2003-04-04 2006-09-28 ファルマシア コーポレーション 複合粒状体からなる経口徐放性圧縮錠
CA2529984C (en) 2003-06-26 2012-09-25 Isa Odidi Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
JP2006528189A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質産物、その使用法および製剤
EP1648407A4 (de) * 2003-07-21 2011-08-31 Middlebrook Pharmaceuticals Inc Antibiotisches produkt, seine verwendung und formulierung
WO2005009364A2 (en) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
EP1653925A1 (de) 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Robustes pellet
JP2007502294A (ja) 2003-08-12 2007-02-08 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
EP1658034A4 (de) 2003-08-29 2011-06-22 Middlebrook Pharmaceuticals Inc Antibiotisches produkt, seine verwendung und formulierung
CA2538064C (en) * 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2007519608A (ja) * 2003-09-19 2007-07-19 ペンウェスト ファーマシューティカルズ カンパニー 時間治療用剤形
JP2007505921A (ja) * 2003-09-19 2007-03-15 ペンウェスト ファーマシューティカルズ カンパニー 遅延放出剤形
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US7387793B2 (en) * 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
AU2004308419B2 (en) * 2003-12-24 2011-06-02 Victory Pharma, Inc. Enhanced absorption of modified release dosage forms
NZ549838A (en) * 2004-03-26 2010-04-30 Eisai R&D Man Co Ltd Coated controlled-release preparation containing a gastric acid secretion inhibitor
US7404970B2 (en) * 2004-04-13 2008-07-29 Konec, Inc. Pain relief composition, method to form same, and method to use same
AU2005264864B2 (en) 2004-06-16 2011-08-11 Takeda Pharmaceutical Company Limited Multiple PPI dosage form
WO2006004774A2 (en) * 2004-06-28 2006-01-12 Stanford University Laulimalide analogues as therapeutic agents
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
WO2006014427A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
US20060105039A1 (en) 2004-10-21 2006-05-18 Jin-Wang Lai Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060121112A1 (en) * 2004-12-08 2006-06-08 Elan Corporation, Plc Topiramate pharmaceutical composition
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
AU2006235483B2 (en) * 2005-04-12 2010-11-25 Elan Pharma International Limited Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection
US9161918B2 (en) * 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
AU2006294581B2 (en) 2005-09-27 2011-11-03 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20090148519A1 (en) * 2005-09-29 2009-06-11 Yasuhiro Zaima Pulsed-release preparation having improved disintegration properties in vivo
EA200801081A1 (ru) * 2005-10-14 2008-10-30 Х. Лундбекк А/С Способы лечения расстройств центральной нервной системы комбинацией малых доз эсциталопрама и бупропиона
US20070112075A1 (en) * 2005-10-14 2007-05-17 Forest Laboratories, Inc. Stable pharmaceutical formulations containing escitalopram and bupropion
WO2007059372A2 (en) * 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
KR101405545B1 (ko) * 2005-11-28 2014-07-03 마리누스 파마슈티컬스 ｇａｎａｘｏｌｏｎｅ 제형, 이의 제조방법 및 용도
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
BRPI0620236A2 (pt) * 2005-12-23 2011-11-01 Lek Pharmaceuticals péletes dilacerantes
US20090069275A1 (en) * 2006-02-17 2009-03-12 Rocca Jose G Low flush niacin formulation
US9561188B2 (en) 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
ES2351527T3 (es) 2006-05-30 2011-02-07 Intarcia Therapeutics, Inc Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración.
EP2359808B1 (de) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotisches Verabreichungssystem mit Kolbenanordnung
ATE510538T1 (de) 2006-08-11 2011-06-15 Univ Johns Hopkins Zusammensetzungen und verfahren für nervenschutz
US8124598B2 (en) * 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
DK2081435T3 (en) 2006-09-22 2016-08-15 Pharmacyclics Llc INHIBITORS OF BRUTON'S TYROSINKINASE
WO2008062320A2 (en) * 2006-10-06 2008-05-29 Eisai R&D Management Co., Ltd Extended release formulations of a proton pump inhibitor
EP2101735A2 (de) 2006-11-28 2009-09-23 Marinus Pharmaceuticals, Inc. Nanoteilchenförmige formulierungen und verfahren zur herstellung und verwendung
US8795721B2 (en) * 2006-12-18 2014-08-05 Eatlittle Inc. Device for delivery of a substance
AU2007340129B2 (en) 2006-12-26 2012-02-02 Pharmacyclics Llc Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
US20080187579A1 (en) * 2007-02-01 2008-08-07 Pavan Bhat Extended-release dosage form
EP2157967B1 (de) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspensionsformulierungen insulinotroper peptide und ihre verwendung
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
MX2010002712A (es) 2007-09-10 2010-06-09 Calcimedica Inc Compuestos que modulan calcio intracelular.
JP5629581B2 (ja) * 2007-10-12 2014-11-19 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド 食物の摂取から独立した消化器疾患の治療方法
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
FR2930147B1 (fr) * 2008-04-18 2013-02-08 Flamel Tech Sa Forme orale solide dotee d'un double profil de liberation
US20110207718A1 (en) 2008-08-06 2011-08-25 Gosforth Centre (Holdings) Pty Ltd. Compositions and methods for treating psychiatric disorders
BRPI0917719A2 (pt) 2008-08-27 2019-11-19 Calcimedica Inc compostos que modulam cálcio intracelular
KR101264961B1 (ko) * 2008-11-07 2013-05-16 주식회사 삼양바이오팜 메칠페니데이트의 방출 제어용 약제학적 조성물
US20100158905A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Combination therapy of arthritis with tranilast
JP5698683B2 (ja) 2009-03-09 2015-04-08 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 治療薬のパルス放出組成物
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
DK2421901T3 (en) 2009-04-24 2016-01-11 Tissue Tech Inc Compositions comprising HC-HA complex, and methods of use thereof
US8808257B2 (en) * 2009-08-31 2014-08-19 Johnson & Johnson Vision Care, Inc. Methods and apparatus for pulsatile release of medicaments from a punctal plug
EP3323423B1 (de) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Schnelle initiierung und/oder beendigung der verabreichung substantiell stabiler arzneimittel
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
CA2782285A1 (en) 2009-12-02 2011-06-09 Luigi Mapelli Fexofenadine microcapsules and compositions containing them
WO2011130689A1 (en) 2010-04-15 2011-10-20 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
JP6112486B2 (ja) 2010-04-27 2017-04-12 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
EP2563759B1 (de) 2010-04-27 2022-04-06 Calcimedica, Inc. Verbindungen als modulatoren von intrazellulärem calcium
ES2688072T3 (es) 2010-05-11 2018-10-30 Mallinckrodt Ard Ip Limited ACTH para el tratamiento de la esclerosis lateral amiotrófica
US9079891B2 (en) 2010-08-27 2015-07-14 Calcimedica, Inc. Compounds that modulate intracellular calcium
US8796416B1 (en) 2010-10-25 2014-08-05 Questcor Pharmaceuticals, Inc ACTH prophylactic treatment of renal disorders
GB201100786D0 (en) 2011-01-18 2011-03-02 Ems Sa Pharmaceutical compositions of immunosuppressants
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012149486A1 (en) 2011-04-28 2012-11-01 Tissuetech, Inc. Methods of modulating bone remodeling
BR112013029199B1 (pt) 2011-05-13 2022-02-08 Eb Ip Hybritabs B.V. Dispositivo de distribuição de dois fármacos
ES2822301T3 (es) 2011-06-10 2021-04-30 Tissuetech Inc Métodos de procesamiento de tejidos de soporte fetal
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
RU2609833C2 (ru) 2011-09-13 2017-02-06 Фармасайкликс Элэлси Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение
EP2586429A1 (de) 2011-10-26 2013-05-01 Freund Pharmatec Ltd. Arzneimittelabgabevorrichtung mit mehreren Einheiten für pulsierende oder verzögerte Freisetzung
US20140326056A1 (en) * 2011-11-30 2014-11-06 D.E.S. Diagnostics Ltd Method for Quick Assessment of Osmolarity
US20140357971A1 (en) * 2011-11-30 2014-12-04 Diagnostear Ltd. Dry eye diagnostic
CN104185420B (zh) 2011-11-30 2017-06-09 埃默里大学 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
SG11201403931YA (en) 2012-02-22 2014-08-28 Duchesnay Inc Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
ES2846789T3 (es) 2012-07-11 2021-07-29 Tissuetech Inc Composiciones que contienen complejos HC-HA/PTX3 y métodos de uso de los mismos
DK2900674T3 (en) 2012-09-28 2017-07-03 Univ Washington Through Its Center For Commercialization RELATIONSHIPS AND PROCEDURES FOR PREVENTION, TREATMENT AND / OR PROTECTION AGAINST SENSITIVE CELL DEATH
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2732803B1 (de) * 2012-11-19 2018-04-25 Follmann GmbH & Co. KG Thermisch öffnende stabile Kern/Schale-Mikrokapseln
CA2896993C (en) * 2013-01-02 2016-12-20 Eatlittle Inc. Pseudobezoar-based intraluminal gastrointestinal transplant
GB201303781D0 (en) 2013-03-04 2013-04-17 Gauthier Pierre Pascal Oral timer device and method of using same
EP2968475A2 (de) 2013-03-14 2016-01-20 Questcor Pharmaceuticals, Inc. Acth zur behandlung des akuten atemstresssyndroms
EP3024466B1 (de) 2013-07-22 2018-04-04 Duchesnay Inc. Zusammensetzung zur behandlung von übelkeit und erbrechen
WO2015054283A1 (en) 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
AU2014347357A1 (en) 2013-11-11 2016-06-16 Limoxifen B.V. Methods and pharmaceutical formulations for treatment of selective estrogen-receptor modulator-induced adverse drug reactions
US20150133516A1 (en) 2013-11-13 2015-05-14 Brian K. Adams Methods and Compositions for Treating ADHD
KR20160093675A (ko) 2013-12-05 2016-08-08 파마싸이클릭스 엘엘씨 브루톤 티로신 키나제의 억제제
US10383944B2 (en) * 2014-04-08 2019-08-20 Dow Global Technologies Llc Dispersion comprising an esterified cellulose ether
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CA2936748C (en) 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US10174275B2 (en) 2015-01-30 2019-01-08 Follmann Gmbh & Co. Kg Thermally opening stable core/shell microcapsules
ES2760373T3 (es) 2015-02-06 2020-05-13 Univ Washington Compuestos y procedimientos para prevenir o tratar la muerte de células ciliadas sensoriales
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
WO2016138025A2 (en) 2015-02-23 2016-09-01 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
CA2977521C (en) 2015-02-27 2024-03-19 Curtana Pharmaceuticals, Inc. 1-(aryl)-3-(heteroaryl) urea compounds and their use as olig2 inhibitors
ES2761616T3 (es) 2015-05-01 2020-05-20 Diagnostear Ltd Método para medir los componentes lagrimales en una muestra lagrimal
CN107847526A (zh) 2015-05-20 2018-03-27 组织技术公司 用于预防上皮细胞的增殖和上皮‑间充质转换的组合物和方法
MA44390A (fr) 2015-06-03 2019-01-23 Intarcia Therapeutics Inc Systèmes de mise en place et de retrait d'implant
AU2016288643A1 (en) 2015-07-02 2018-02-22 University Of Louisville Research Foundation, Inc. Edible plant-derived microvesicle compositions for delivery of miRNA and methods for treatment of cancer
EP3827838B1 (de) 2015-12-16 2023-06-07 The Walter and Eliza Hall Institute of Medical Research Hemmung von cytokininduziertem sh2-protein in nk-zellen
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
SG11201810102SA (en) 2016-05-16 2018-12-28 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof
WO2017205534A1 (en) 2016-05-25 2017-11-30 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
GB2551980A (en) * 2016-06-30 2018-01-10 Commw Scient Ind Res Org Method and system for low level metal analysis of mineral samples
KR102518846B1 (ko) 2016-08-11 2023-04-05 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
SG11201901679XA (en) 2016-08-26 2019-03-28 Curtana Pharmaceuticals Inc Inhibition of olig2 activity
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
WO2019039937A1 (en) 2017-08-21 2019-02-28 Stichting Vumc POLYTHERAPY FOR THE TREATMENT OF CANCER
EP3706735A1 (de) 2017-11-06 2020-09-16 Snap Bio, Inc. Pim-kinaseinhibitorzusammensetzungen, verfahren und ihre verwendungen
WO2019169112A1 (en) 2018-02-28 2019-09-06 Curtana Pharmaceuticals, Inc. Inhibition of olig2 activity
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly
AU2019310118A1 (en) 2018-07-27 2021-03-11 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic TRPV1 agonists
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
SG11202106304RA (en) 2018-12-31 2021-07-29 Biomea Fusion Llc Irreversible inhibitors of menin-mll interaction
EP3937938A1 (de) 2019-03-15 2022-01-19 Unicycive Therapeutics Inc. Nicorandilderivate
MX2022001553A (es) 2019-08-05 2022-04-18 Marinus Pharmaceuticals Inc Ganaxolona para su uso en el tratamiento del estado epileptico.
MX2022006014A (es) 2019-12-06 2022-06-22 Marinus Pharmaceuticals Inc Ganaxolona para uso en el tratamiento del complejo de esclerosis tuberosa.
WO2022133064A1 (en) 2020-12-16 2022-06-23 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
CA3204457A1 (en) 2021-01-06 2022-07-14 Ben SESSA Mdma in the treatment of alcohol use disorder
EP4337316A1 (de) 2021-05-11 2024-03-20 Awakn Ls Europe Holdings Limited Therapeutische aminoindanverbindungen und zusammensetzungen
EP4346788A2 (de) 2021-06-03 2024-04-10 Arcadia Medicine, Inc. Enantiomere entactogenzusammensetzungen und verfahren zu deren verwendung
WO2023018825A1 (en) 2021-08-11 2023-02-16 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
WO2023039240A1 (en) 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
TW202340177A (zh) 2021-12-30 2023-10-16 美商拜歐米富士恩股份有限公司 作為 flt3抑制劑之吡嗪化合物
WO2023139163A1 (en) 2022-01-19 2023-07-27 Awakn Ls Europe Holdings Limited 1,3-benzodioxole esters and their therapeutic use
WO2023156565A1 (en) 2022-02-16 2023-08-24 Awakn Ls Europe Holdings Limited Bridged ring compounds and their therapeutic use as cns agents
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL52914C (de) * 1937-11-24
US3247066A (en) * 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
US4177256A (en) * 1973-04-25 1979-12-04 Alza Corporation Osmotic bursting drug delivery device
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
DE3586600T2 (de) * 1984-02-10 1993-02-18 Benzon Pharma As Dosierungsform eine vielzahl mit einer diffusionshuelle ueberzogener einheiten enthaltend.
US4863744A (en) * 1984-09-17 1989-09-05 Alza Corporation Intestine drug delivery
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US5110597A (en) * 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
AU634529B2 (en) * 1989-03-17 1993-02-25 Pitman-Moore, Inc. Controlled release delivery device for macromolecular proteins
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5017381A (en) * 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system

Also Published As

Publication number Publication date
US5260069A (en) 1993-11-09
EP0670718B1 (de) 2001-10-10
ES2165869T3 (es) 2002-04-01
CA2149152C (en) 2003-09-30
ATE206613T1 (de) 2001-10-15
JPH08506802A (ja) 1996-07-23
DE69330910D1 (de) 2001-11-15
WO1994012160A1 (en) 1994-06-09
AU5549294A (en) 1994-06-22
CA2149152A1 (en) 1994-06-09
EP0670718A4 (de) 1996-10-09
US5472708A (en) 1995-12-05
EP0670718A1 (de) 1995-09-13
AU680642B2 (en) 1997-08-07
NZ258012A (en) 1996-10-28

Similar Documents

Publication Publication Date Title
DE69330910T2 (de) Arzneiabgabesystem mit stossweiser freisetzung von partikeln
ATE215818T1 (de) Multipartikel-arzneistoffabgabesystem mit stossweiser freisetzung
CA2294744C (en) Multiple unit effervescent dosage form
KR890006223A (ko) 약물방출계
KR920703026A (ko) 부하제를 포함한 장기간 전달 장치
NZ508567A (en) Methods and devices for providing prolonged drug therapy
ATE165734T1 (de) Arzneitablette, die befähigt ist, einen oder mehrere wirkstoffe mit unterschiedlichen abgaberaten freizusetzen
ATE269709T1 (de) Tablette mit verzögerter freigabe enthaltend einen blutzuckersenkenden wirkstoff und einen antihyperglyzemischen wirkstoff
ZA912380B (en) Osmotic dosage system for liquid drug delivery
ATE238774T1 (de) Darreichungsform zur verzögerten, vollständigen wirkstoffabgabe im verdauungstrakt
ATE285228T1 (de) Arzneistoffverabreichungsystem zur verzögerten, völlstandigen wirkstoffabgabe im verdauungstrakt
DK0673645T3 (da) Farmaceutisk præparat til afgivelse af lægemidler i colon
JPS62267221A (ja) 新規薬物製剤
ATE211649T1 (de) Dosisform mit gesteuerter freigabe für kalium
IE882898L (en) Solubility modulated drug delivery device
Helfand et al. Evolution of pharmaceutical oral dosage forms
KR940701285A (ko) 소수성 부하물을 함유하는 지효성 전달 장치
US4454142A (en) Hyperkinetic child treatment agent
Freed et al. Amphetamine-resin complex for prolonged appetite suppression
US6663896B1 (en) Delayed release aspirin for vascular obstruction prophylaxis
CN100522168C (zh) 罗通定缓释胶囊及其制备方法

Legal Events

Date Code Title Description
8364 No opposition during term of opposition